The Omeza Protocol for Chronic Ulcers

Last updated: April 8, 2021
Sponsor: Omeza, LLC
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes And Hypertension

Ulcers

Venous Leg Ulcers

Treatment

N/A

Clinical Study ID

NCT04198441
Protocol Number: 100
  • Ages 21-80
  • All Genders

Study Summary

This study will compare the Omeza® Products Bundle to standard of care (SOC) for in subjects with chronic venous leg ulcers and subjects with diabetic foot ulcers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female 21-80 years of age
  2. Participated in the informed consent process and signed study specific informedconsent document
  3. Willing and able to comply with study procedures, including study visits and studydressing regimens
  4. Confirmation of venous disease by non-invasive venous studies with either Doppler-confirmed venous reflux or having ≥ 2 clinical characteristics of venous insufficiency (varicose veins, lipodermatosclersosis, venous dermatitis, atrophie blanche, edema).Biopsy done to exclude other skin conditions e.g. cancer on ulcers ≥ 6 months
  5. HbA1c of ≤ 10%
  6. Have a venous ulcer between the knee and ankle, at or above the malleolus
  7. For VLU's: Target wound size ≥ 4 cm2 to ≤ 150 cm2 in area without exposed tendon,muscle or bone For DFU's: Target wound size ≥ 0.25 cm2 to ≤ 150 cm2 post debridementat Screening Visit and Treatment Visit Week 1/Randomization
  8. Target wound duration of at least 3 months and less than or equal to 12 months as ofthe date the subject signs consent for study
  9. Containing yellow/white slough with or without fibrous/scar tissue and/or non- viabletissue
  10. Be willing and able (or have family member/friend willing and able) to apply requireddressing changes as well as the ability of the subject to tolerate limb compressionbandage
  11. Ankle-Branchial Index (ABI) less than 0.80 or greater than 1.3

Exclusion

Exclusion Criteria:

  1. Subjects with a BMI ≥ 65
  2. Subject is medically unable to consent (due to head trauma, coma, etc.) or cognitivelyimpaired (due to being mentally challenged, having Alzheimer

Study Design

Total Participants: 78
Study Start date:
June 02, 2020
Estimated Completion Date:
December 31, 2021

Study Description

This is a randomized, multi-center, open-label study comparing the Omeza® Products Bundle versus standard of care treatments for 2 different types of chronic ulcers (venous leg ulcers and diabetic foot ulcers). The treatment period will be 12 weeks, with subjects coming into the study site weekly for evaluations, photography and formal measurements of the target wound, and dressing changes. There will be a total of 13 study site visits. The Screening Visit (Day 0) will occur 1 week prior to randomization and will include routine labs and vascular assessment to determine inclusion/exclusion of the potential subject from the study; followed by weekly treatment visits (Week 1 through Week 11); randomization will occur at Treatment Visit Week 1; the Treatment Visit Week 12/End of Study Visit will include end of study labs. Target wounds will be photographed and measured, and vascular assessment will be done at each of the 13 visits.

If the wound closes before Week 12, the subject will continue to come in for all the remaining study visits until study completion. If the wound does not close by Week 12, the subject will be immediately exited from the study and no further follow-up will occur as part of the study.

Connect with a study center

  • First Coast Cardiovascular Institute

    Jacksonville, Florida 32256
    United States

    Active - Recruiting

  • Saint Michael's Medical Center

    Newark, New Jersey 07102
    United States

    Active - Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon 97239
    United States

    Active - Recruiting

  • Baylor Scott & White Comprehensive Wound Care Center

    Dallas, Texas 75246
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.